CareDx ( (CDNA) ) has issued an announcement.
On March 27, 2025, CareDx, Inc. announced an Amended and Restated Change of Control and Severance Agreement with its CFO, Abhishek Jain. This agreement outlines severance benefits for Mr. Jain in the event of a change of control or termination, impacting the company’s executive compensation structure and potentially influencing stakeholder perceptions regarding leadership stability.
More about CareDx
CareDx, Inc. operates in the healthcare industry, focusing on providing diagnostic solutions for transplant patients. The company specializes in developing and commercializing clinically differentiated, high-value diagnostic surveillance solutions for organ transplant recipients.
YTD Price Performance: -14.73%
Average Trading Volume: 846,344
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
See more insights into CDNA stock on TipRanks’ Stock Analysis page.